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An attenuated equine infectious anemia virus (EIAV), V26, was previously prepared by 50 passages of the Japanese virulent
strain V70 in primary horse macrophage culture. The horses inoculated with this V26 virus were shown to raise neutralizing
antibodies against V70 without any viremia. Here, we investigated the in vitro and in vivo replication ability of V26.
Comparison of the long-terminal repeat (LTR) sequences between V26 and V70 revealed a large insertion within the LTR U3
hypervariable region of V26. V26 with the mutation in the LTR showed much higher promoter activity in vitro than V70. This
is consistent with the much higher replication rate of V26 in horse primary macrophage cultures compared with V70. In sharp
contrast, we failed to identify the V26-specific LTR sequence by PCR, at least in sequential samples of plasma or peripheral
blood mononuclear cells derived from three horses until day 62 after V26 inoculation. In contrast, antibody responses to EIAV
were observed in all horses. The results suggest that the replication ability of V26 in vivo is extremely low. When one of the
horses was subsequently challenged with cell-associated V70, it was found that the horse became PCR positive for EIAV.
There was no LTR mutation in EIAV genome in samples periodically prepared from the V70-challenged horse. Thus it was
suggested that the LTR mutation in EIAV, which occurs during serial passage in vitro, affects EIAV replication in vitro and in
vivo. © 2000 Academic PressINTRODUCTION
Equine infectious anemia (EIA) virus (EIAV), a lentivirus
with nucleotide sequence relatedness to human immu-
nodeficiency virus (HIV), particularly in pol reverse tran-
scriptase (RT) (52.8% homology) (Chiu et al., 1985),
causes acute, chronic, and subclinical diseases in
horses characterized by repeated recurrence of febrile
attacks, anemia, ventral edema, anorexia, and weight
loss (Sellon et al., 1994). Most of these episodes occur
within 1 year from the initial infection, after which the
surviving horses remain asymptomatic carriers of the
virus. EIAV transmission can occur in horses injected
with whole blood, washed leukocytes, or cell-free serum
or plasma from infected asymptomatic carriers (Issel and
Coggins, 1979). Because a high percentage of infected
horses develop serviceable immunity against EIAV-in-
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12duced disease (Montelaro et al., 1989), prophylactic vac-
cines for EIA have been developed and evaluated in
Japan, China, and the United States (Kono and Koba-
yashi, 1970; Shen, 1983; Issel et al., 1992).
Virus attenuation is a general phenomenon observed
during successive passages of a virulent virus in tissue
culture. Kobayashi and Kono (1967a, 1967b) succeeded
in cultivating EIAV in primary horse macrophage culture.
Using this culture system, an attenuated EIAV, V26, was
obtained after 50 passages of the virulent strain of Jap-
anese EIAV (V70) in primary horse macrophages (Kono
and Kobayashi, 1970). Horses infected with V26 success-
fully acquired resistance to challenge with cell-free vir-
ulent V70 but not with another virulent EIAV strain, Wyo-
ming (Kono et al., 1970). Similarly, attenuated EIAV was
developed by 123 passages of the Chinese virulent strain
in donkey macrophages (Shen, 1983). This attenuated
EIAV has been widely used as a prophylactic vaccine in
China. When vaccinated horses and donkeys were chal-
lenged with three cell-free Chinese EIAV strains (L, H,
and Y), the protection rates were more than 80% (Shen,
1983). This vaccination was also reported to protect
horses from challenge with the wild-type cell-free Wyo-
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130 ZHENG ET AL.ming strain at a rate of more than 80% (Shen et al., 1990).
owever, it remains unknown how this kind of attenu-
ted EIAV loses virulence in vivo.
It is noteworthy that in V26-inoculated horses, there
ere detectable neutralizing antibodies as well as com-
lement-fixing (CF) antibodies. However, a previous
tudy showed that no virus was recovered from sera of
26-inoculated horses using horse primary macrophage
ultures (Kono et al., 1970). Here, we showed that the
large insertion mutations in the long-terminal repeat
(LTR) confer much higher promoter activity on V26 com-
pared with V70. In contrast, we detected no V26-specific
sequences in at least sequential samples of plasma or
peripheral blood mononuclear cells (PBMCs) from three
V26-inoculated horses through polymerase chain reac-
tion (PCR), although antibodies against EIAV were raised
significantly. These results suggested that the replication
FIG. 1. Growth properties of V70 and V26 in horse primary macro-
hage culture. Horse primary macrophages were infected with the
ame amount of V70 or V26 strain, which were adjusted by RT activity.
he cell-free supernatants were collected daily for 5 days. RT activity
as quantified by photostimulative luminescence.FIG. 2. Comparison of the nucleotide consensus sequences for LTR betwe
dashes indicate a gap.ability of V26 in vivo is extremely low. This could be one
of the reasons why the V26 has lost the virulence of the
original V70 in horses.
RESULTS
Comparison of replication ability between V26 and
V70 in vitro
Generally, serial passage in vitro of virulent viruses
induces attenuation, concomitant with the acquisition of
higher replication ability. V26, obtained by 50 passages
of virulent V70 in horse primary macrophages, was pre-
viously shown to have lost its virulence in horses (Kono
and Kobayashi, 1970). Therefore, we compared the rep-
lication rates between V26 and the original V70 in horse
primary macrophage cultures. The virus production rates
were sequentially estimated by RT activity in conditioned
medium. Three independent experiments showed es-
sentially similar results. As shown in Fig. 1 as a repre-
sentative, the V26 showed higher RT activity than V70
(i.e., 1.8-fold higher on day 4 and 1.5-fold higher on day 5
after infection). Thus V26 shows higher replication rate in
vitro than V70.
Sequence differences in LTR between V26 and V70
A high level of mutation at the LTR U3 region of EIAV
was shown to be induced in passage in vitro (Maddon
and Shih, 1996). Therefore, we examined the nucleotide
sequence difference between V26 and V70 at the LTR.
The l-vectors containing the 59 half of the V26 and V70
provirus genomes were obtained from cellular DNAs
prepared from V26- and V70-infected macrophages, re-
spectively. The regions including LTR were amplified
from the l-vectors by PCR using sense primer LTR-D01
nd antisense primer LTR-A01. The PCR fragments were
loned into the pCR vector and then sequenced (Fig. 2).
e found a large insertion within the U3 region of V26,en V26 and V70. Points indicate identity with V70 at that position, and
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131REPLICATION OF EIAV AVIRULENT STRAINand this region was previously found to be hypervariable
(Carpenter et al., 1991).
Comparison of the U3 sequences of V26 and V70
with those of other EIAV strains
First, we compared the sequences at the U3 hyper-
variable region of V26 and V70 with those of other re-
ported EIAV strains: wild-type Wyoming strain (Perry et
al., 1992), Th-1 strain (Carpenter et al., 1991), MA-1 strain
(Carpenter et al., 1991), Malmquist strain-derived 1369
(Kawakami et al., 1987), CL.22 (Perry et al., 1992), pS-
EIAV19 (Payne et al., 1994), pSPEIAV44 (Payne et al.,
994), l-12 (Carvalho et al., 1993), ALTR3 (Madden and
Shih, 1996), and ALTR4 (Madden and Shih, 1996), as
shown in Fig. 3. The sequences were exactly the same
between V70 and wild-type Wyoming strain, both of
which are not cell culture adapted. The origin of the
insertion sequence found in V26 is unknown, because
we could not find sequence similarity in the insertion
portion among V26 and Malmquist strain-derived se-
quences. The MDBP and CAAT sequences detected in
V70 were not detected in V26. In contrast, two new
potential ets motifs (GTTCt and cTTCC) were found in
V26. Next, we examined the possible effects of this
sequence variation on promoter activity of V26 and V70.
Comparison of promoter activity between V26
and V70
To assess the impact of sequence variation within the
U3 region on promoter strength, the U3 sequences of
V26 and V70 were cloned into pGL3 vector. Transient
gene expression assays were performed using Cf2Th
cell cultures, because a previous studies showed that
Cf2th cells were permissive for EIAV transactivation as
FIG. 3. Comparison of the U3-LTR hypervariable region of various E
etters indicate variant nucleotides, and dashes indicate gaps.well as for replication of cell culture-adapted EIAV strains
(Maury et al., 1994; Payne et al., 1999). As shown in Fig.
m
b, the measurements showed that pGL3-V70 without tat
otransfection had the minimum luciferase activity. The
GL3-V26 without tat, pGL3-V70 with tat, and pGL3-con-
rol had similar levels of luciferase activities. Surprisingly,
GL3-V26 with tat showed much higher luciferase activ-
ties than others: nearly eightfold higher than pGL3-V70
ith tat. Thus V26 has much higher promoter activity than
70 under tat-transactivation condition. This result is
onsistent with the observation that V26 showed higher
eplication ability in vitro than V70 (Fig. 1). Therefore, we
ext examined whether the high promoter activity and
igh replication ability of V26 in vitro are reflected in vivo.
eplication ability of V26 in horses
To compare the replication ability of V26 in vivo, we
noculated three horses (701, 706, and 707) with V26
train (Fig. 5). To confirm that V26 was successfully
noculated in these horses, the antibody response
gainst EIAV in sera of these horses was first determined
sing CF, enzyme-linked immunosorbent assay (ELISA),
nd agar gel immunodiffusion (AGID) tests. Anti-Gag p26
ntibodies were initially detected in horse 701 on day 10,
n horse 706 on day 23, and in horse 707 on day 16 after
26 inoculation by CF test. Both assays revealed that V26
noculations raised significant amounts of EIAV-specific
ntibodies in these horses. Because the immune re-
ponse against EIAV was confirmed in all these horses
noculated with V26, we next attempted to detect V26
roviral DNA by PCR in PBMCs and viral RNA by RT-PCR
n plasma from the inoculated horses.
Previous studies showed that the major EIAV reservoir
n vivo is monocytes and that monocyte maturation con-
rols EIAV expression (Sellon et al., 1992, 1996; Maury,
994). Therefore, virus replication in vivo should be
ains. Putative transcription factor binding sites are boxed. Lowercaseostly reflected by the detection of proviral DNA har-
ored in monocytes and viral RNA in plasma. PBMCs
GL3-Ba
tions f
132 ZHENG ET AL.and plasma samples were periodically isolated from
these three horses until day 62 after V26 inoculation. The
cellular DNAs from the PBMCs were subjected to PCR
and total RNAs in plasma were subjected to RT-PCR to
amplify the LTR-U3 region, which was the major region to
differentiate both strains. Usually proviral DNA can be
detected from PBMCs on days 5–16 after EIAV infection
(Rice et al., 1989; Whetter et al., 1990; Payne et al., 1994).
However, we failed to detect the EIAV-specific signals in
PBMCs and plasma from all three horses until day 62
after V26 inoculation. The results from horse 701 were
shown in Fig. 6. There also were no clinical signs in
these horses until day 62 after inoculation (Fig. 5).
Because we were unable to detect EIAV genome in all
three horses after V26 inoculation, we next inoculated
one of the horses (701) with cell-free V70 strain on day 62
after V26 inoculation. Even though we continued to de-
tect EIAV genome in this horse until day 102, the results
were still negative. On day 102 after V26 inoculation, this
horse was again inoculated with cell-associated V70
strain. This horse developed typical clinical signs with
FIG. 4. Promoter activity assay of the V70 and V26 strains using DLR
cotransfected with or without pZeoSV-tat plasmid into the Cf2th cells tog
Methods. The pGL3-Basic vector containing no promoter sequence a
were used as negative and positive controls, respectively. After 48 h, t
shown as relative values of individual samples compared with the p
normalized by the internal control. Error bars represent standard deviaperiodical relapse of fever on days 136, 165, 204, 234,
258, 413, and 453. The data until day 170 were shown inFig. 5. On day 136, the PCR and RT-PCR signals changed
to positive and the positive signals continued through
day 453 (Fig. 6). To determine whether these positive
signals were derived from V26 or V70, the PCR and
RT-PCR products from horse 701 were directly ligated
into the pCR vector. Several clones randomly selected
from each product were then sequenced, and the results
are summarized in Fig. 7. The sequences of these clones
(clones 19–36 derived from PBMCs and 38–44 derived
from plasma) had no apparent differences from the se-
quence of V70 strain LTR U3 region. In total, we se-
quenced 93 cDNA clones (71 clones derived from PB-
MCs and 22 clones derived from plasma) and found no
V26 strain-derived LTR U3 sequences. Therefore, we
conclude that the positive PCR and RT-PCR signals am-
plified from PBMCs and plasma should be predominantly
derived from V70 strain.
No apparent sequence variation at LTR U3 region
in EIAV during replication in vivo
system in Cf2th cell culture. pGL3-V70 and pGL3-V26 plasmids were
ith the internal control plasmid pRL-TK, as described in Materials and
3-Control vector containing SV40 promoter and enhancer sequences
s were harvested and assayed for dual-luciferase activity. Results are
sic vector luciferase activity, after the activities of all samples were
rom the mean for results of five independent assays.assay
ether w
nd pGL
he cellA high level of mutation at the LTR U3 region of V70
was induced during serial passage in vitro in horse
observ
after V
133REPLICATION OF EIAV AVIRULENT STRAINprimary macrophage cultures (Fig. 2). To determine the
level of LTR U3 region variation of V70 in vivo, the se-
quences from multiple LTR clones derived from PBMCs
and plasma of horse 701 at different stages after the V70
infection were compared (Fig. 7). There were almost no
mutations in most of the PBMCs-derived clones (19–23
and 30–36) and plasma-derived clones (38–44). A slightly
higher substitution was observed in the hypervariable
region in part of the PBMC-derived clones (24–29), even
though the substitutions were no more than two nucle-
otides. Nucleotide mutations were observed at such a
low frequency, so we may conclude that during V70
replication in vivo, the sequence diversity within the LTR
U3 region is extremely low.
DISCUSSION
FIG. 5. Clinical history and anti-EIAV antibody response of three horse
V70. Horses 701, 706, and 707 were inoculated with V26. Their clinical h
antibody responses to EIAV by CF, ELISA, and AGID tests (bottom) were
with cell-free V70 on day 62 and with cell-associated V70 on day 102A large insertion was observed within the LTR U3
region of V26 in addition to several base substitutionsthroughout the LTR compared with the sequence of V70
(Fig. 2). These mutations at the LTR conferred higher
promoter activity on V26 than V70 (Fig. 4). Despite the
high replication ability in primary macrophage cultures in
vitro (Fig. 1), we could not detect any V26-specific se-
quences in PBMCs or plasma from V26-inoculated
horses (Fig. 6).
During acute EIAV infection, PBMCs usually allow viral
entry and reverse transcription of viral RNA to DNA but
do not support active EIAV replication (Sellon et al., 1996).
In fact, no viral RNA can be detected in the PBMCs, and
only proviral DNA can be detected (Rice et al., 1989). The
monocytes in PBMCs may serve as a reservoir for the
virus, and when these monocytes differentiate into mac-
rophages, viral transcription and replication are up-reg-
ulated (Sellon et al., 1992; Maury, 1994). Therefore, we
tried to detect the proviral DNA by PCR analyses in
lated with V26, followed by challenge with cell-free and cell-associated
[top: body temperature (°C) and numbers of days postinoculation] and
ed until day 62 after V26 inoculation. Horse 701 was further challenged
26 inoculation.s inocu
istoryPBMCs from horses after V26 infection. Usually, proviral
DNA can be detected from PBMCs on days 5–16 after
134 ZHENG ET AL.EIAV infection (Rice et al., 1989; Whetter et al., 1990;
Payne et al., 1994). However, we failed to detect proviral
DNA in all three V26-inoculated horses until day 62 (Fig.
6). Therefore, we next challenged one of these horses
(701) with cell-free and cell-associated V70 on days 62
and 102, respectively, and continued to follow viral ge-
nome in PBMCs and plasma. From day 136 after V26
inoculation, which was also the first febrile episode after
V70 challenge (Fig. 5), we were able to detect the EIAV
FIG. 6. EIAV genome in the PBMCs and plasma from horse 701 inoc
Horse 701 was inoculated with V26, followed by challenge with cell-fre
DNAs from the PBMCs and total RNAs in plasma were subjected to P
of each lane indicate the days after V26 inoculation.genomes in both PBMCs and plasma (Fig. 6), and the
genomes were confirmed to be of the V70 type (Fig. 7).These results suggested that unlike V70, V26 failed to
enter monocytes in PBMCs and the replication ability of
V26 in vivo was extremely low, although V26 was able to
infect primary horse macrophages in vitro. This seems to
be one of the reasons why V26 lost virulence in vivo.
V26 lost the ability to replicate at least in PBMCs in
three horses examined, although V26 was obtained by
serial passage of V70 in vitro in the primary horse mac-
rophages, the natural host for EIAV replication in vivo.
ith V26, followed by challenge with cell-free and cell-associated V70.
cell-associated V70, as described in the legend to Fig. 5. The cellular
RT-PCR to amplify the LTR U3 region. The numbers shown at the topulated w
e and
CR andHowever, these three horses inoculated with V26 simi-
larly raised significant amounts of EIAV-specific antibod-
re com
equenc
135REPLICATION OF EIAV AVIRULENT STRAINies (Fig. 5). One explanation for this discrepancy is the
possibility that the antibodies were raised against the
V26 antigens in the inoculum, because we inoculated
these horses with a high dose of V26. Another explana-
tion is that V26 could replicate in certain cells other than
PBMCs, such as the mature macrophages at extremely
low levels. Because V26 strain was obtained by serial
passages of V70 in primary macrophage cultures that
originated from monocytes in peripheral blood, it might
be possible that an extremely macrophage-tropic strain
that could not replicate in monocytes in vivo was se-
lected during serial passage in vitro. It was reported that
there was a delay for several days in the appearance of
viral antigen expression in primary horse monocytes in
vitro compared with that in differentiated adherent mac-
rophages (Maury, 1994). In fact, a macrophage-specific
transcription factor, PU-1, that interacts with the proto-
oncogene ets motif (GTTCC) located in the U3 LTR re-
FIG. 7. Multiple nucleotide sequence alignments of LTR U3-containing
from horse 701 after EIAV inoculation, as shown in Fig. 6. Clones 19–36
189, 204, 213, 226, 234, 237, 242, 258, 261, 295, 392, 413, and 453, respec
136, 165, 204, 234, 258, 413, and 453, respectively. These sequences we
indicate identity with original V70 sequence. The V70 strain-specific sgion, was identified (Maury, 1994). Interestingly, two new
potential ets motifs (GTTCt and cTTCC) were found inV26 (Fig. 3), and these new ets sites might increase the
sensitivity of V26 to macrophage-specific transcription
factor during V26 replication in differentiated macro-
phages and may regulate the macrophage-tropic nature
of V26. However, it is necessary to examine whether V26
can directly establish persistent infection in vivo in ma-
ture macrophages in different tissues, such as the liver,
lymph nodes, bone marrow, and spleen.
Similar to V26, a Chinese group also obtained an
attenuated EIAV strain after 123 passages of a Chinese
virulent strain in donkey macrophage culture (Shen,
1983). Although strong immune responses against EIAV
were detected in horses from day 21 and lasted for
several years after immunization with this attenuated
strain, they also failed to detect infectious virus after
inoculating the materials from the liver, spleen, bone
marrow, and peripheral blood of the immunized horses to
other healthy horses (Yu, 1996). This also suggested the
. These clones were derived from the positive PCR or RT-PCR products
pond to the PCR products from PBMCs on days 136, 140, 154, 165, 171,
lones 38–44 correspond to the RT-PCR products from plasma on days
pared with the original LTR U3 sequence of V70 (top sequence). Points
es that were not found in V26 strain are boxed.clones
corres
tively. Cextremely low replication ability of this kind of attenuated
strain in vivo.
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136 ZHENG ET AL.The mechanism for loss of virulence in vivo differs
between V26 and other attenuated strains. In contrast to
V26 and the Chinese attenuated strain, two molecularly
cloned virus strains, CL.22 and pSPEIAV44, can infect
equine PBMCs in vivo (Whetter et al., 1990; Payne et al.,
1994). They can also replicate very well in primary equine
macrophages as well as in equine dermis (ED) cells or
fetal equine kidney cells in vitro. V26 can replicate in
primary macrophages at a higher rate and can also
replicate in fetal equine kidney cells (Kono and Yoshino,
1974) or ED cells (data not shown). In contrast, virulent
strains such as wild-type Wyoming, Th-1, and V70 can
only replicate in primary macrophages in vitro (Koba-
ashi and Kono, 1967b; Carpenter and Chesebro, 1989;
erry et al., 1992). Thus there appears to be no direct
ssociation of the replication ability of EIAVs in primary
acrophages in vitro with their virulence in vivo as well
s their replication ability in vivo. However, the mutation
n V26 LTR as shown in Fig. 3 might be related to the
ttenuation, as two groups recently showed that at least
TR could be the most important candidate to play a
ignificant role in the EIAV-induced pathogenesis (Cook
t al., 1998; Payne et al., 1998).
Our previous study showed that V26 protected horses
from challenge with cell-free V70 but not with the Wyo-
ming strain (Kono et al., 1970). In this study, V26 also
failed to protect against challenge with cell-associated
V70 (Fig. 5). The PND regions of V70 and V26 were
completely the same but markedly differed from the Wy-
oming strain (Zheng et al., 1997a). This difference in PND
might be the major reason for lack of ability of V26 to
protect against challenge with the Wyoming strain. In
addition, cell-associated V70 may be transmissible in
horses even after the immune responses raised by im-
munization with V26. The PND sequences appeared in
the first febrile episode in horse 701 after challenge with
cell-associated V70 included type III, in addition to the
original V70 PND sequence, which belonged to type I
(Zheng et al., 1997b). This might be why V26 failed to
protect the horse from cell-associated V70 challenge. A
large insertion in the LTR U3 region was identified in V26
compared with V70 (Fig. 2). The mutation site was lo-
cated within the hypervariable region of LTR that was
identified by Carpenter et al. (1991). A similar insertion
was observed when EIAVpr strain was passaged in fetal
donkey dermal cell cultures (Madden and Shih, 1996). In
contrast, we found no sequence diversity within the U3
region in V70-inoculated horse 701 (Fig. 6), as also re-
ported previously (Lichtenstein et al., 1996; Maury et al.,
1997). Previously, we identified drastic mutations in the
PND region in viruses isolated from this horse after V70
inoculation (Zheng et al., 1997b). Consequently, the LTR
U3 region might be the major target site of mutation in
EIAV in vitro, whereas the PND region might be the major
target site of mutation in vivo.MATERIALS AND METHODS
Viruses and cell culture
The virulent strain of Japanese EIAV (V70) and the
attenuated strain (V26) obtained after 50 passages of V70
in primary horse macrophage culture have been de-
scribed previously (Kono and Kobayashi, 1970). The V26
and V70 viruses with the same RT activities were used to
infect primary macrophages.
Primary equine adherent macrophage cultures were
established as described previously (Kobayashi and
Kono, 1967b). ED cells (ATCC CCL 57) persistently in-
fected with the Malmquist strain of EIAV (ATCC VR-778)
(Malmquist et al., 1973) and canine fetal thymus cells,
Cf2Th (ATCC CRL 1430), were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum.
Cloning of V26 and V70 proviral genomes at LTR
region
The l-vector containing the 59 LTR, gag, start of pol of
26, or V70 provirus genome was obtained. To obtain the
l-vectors containing the 59 half genome of V70 and V26,
the cellular DNAs from V70- and V26-infected macro-
phages were digested with EcoRI and fractionated by
centrifugation through sucrose density gradients. The
EIAV genome-positive fraction, which was confirmed by
Southern hybridization using a gag-specific probe, was
ligated into l-dash vector (Stratagene, La Jolla, CA).
About 2 million clones were screened with a 1-kb gag
region-specific probe, and several positive clones were
obtained for each V26 and V70 after three rounds of
screening.
PCR amplification at the LTR region from the above
l-vectors was carried out as described previously
(Zheng et al., 1997b). The primers used to amplify these
regions were derived from the sequence of the proviral
clone (CL.22) obtained from the Malmquist strain (Perry
et al., 1992): sense primer LTR-D01 (59-TGTGGGGTTTT-
TATGAGGGGTT-39) at nucleotides 7875–7896 and anti-
sense primer LTR-A01 (59-GCGCCTTGCTCCATGTCA-39)
at nucleotides 461–444.
Blood sample preparation from EIAV-infected horses
and cloning of the EIAV LTR U3 region
Horses 706 and 707 were inoculated with homologous
macrophages (;5 3 107 cells) infected with avirulent
strain, V26. In addition, horse 701 was similarly inocu-
lated with V26, followed by challenge with cell-free viru-
lent strain V70 at day 62 and then with homologous
macrophage-associated strain V70 at day 102. Plasma
and PBMC samples were periodically isolated from
these horses after V26 inoculation. Total RNA and DNA
were extracted from plasma and PBMCs, respectively.
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137REPLICATION OF EIAV AVIRULENT STRAINThe LTR U3 region from each sample was amplified by
RT-PCR or PCR, as described (Zheng et al., 1997b). For
RT-PCR, first-strand synthesis was initiated with an EIAV-
specific primer, LTR-A02 (59-TTTCAGCCCAGCAGAGA-39)
and then amplified by primer pair LTR-D01 and LTR-A02.
For direct PCR, the first PCR was performed with primer
pair LTR-D01 and LTR-A01, and then the second PCR was
performed with primer pair LTR-D01 and LTR-A02. The
specificity of all the PCR and RT-PCR products was
examined by Southern hybridization with an LTR U3-
specific probe, and the positive PCR and RT-PCR prod-
ucts were directly cloned into the pCR vector.
Nucleotide sequencing
After the PCR or RT-PCR fragments were cloned into
the pCR-vector, they were sequenced with a Dye Primer
Cycle Sequencing Ready Reaction Kit using 221 M13 or
M13 Rev or a Taq Dye Terminator Cycle Sequencing Kit
Applied Biosystems, Foster City, CA). Sequences were
esolved by an ABI 373A DNA sequencer (Applied Bio-
ystems), as described previously (Zheng et al., 1997b).
he sequences were analyzed with GENETYX-MAC DNA
equence analysis software (Software Development Co.,
okyo, Japan).
T assay
To estimate the viral replication rates, RT activities in
he conditioned medium of primary macrophage cultures
ere assayed, as described previously (Ogawa et al.,
989). Briefly, the medium was mixed with a reaction
ixture containing poly(rA)/oligo(dT) and [a-32P]dTTP
800 Ci/mmol; DuPont-New England Nuclear, Boston,
A). The reaction mixture was incubated for 3 h at 37°C,
nd aliquots of 10 ml of each reaction mixture were
spotted onto DE81 paper (Whatman, Inc., Clifton, NJ). The
paper was washed five times with 23 SSC and exposed
in a BAS IP cassette, and the activities were analyzed
with MacBAS V 2.0 (Fuji Photograph Film Co., LTD.,
Japan) and quantified by photostimulative luminescence,
as described previously (Fujinaga et al., 1995).
Plasmid construction for promoter activity assay
The EIAV tat gene was amplified from the total RNAs
extracted from ED cells persistently infected with the
Malmquist strain. The amplification was carried out by
RT-PCR with primer pair Tat-D1 (59-ATGCTGGCTGATCG-
TAGGATCCCCGGGACA-39) and Tat-A1 (59-TTATAA-
CAAATATTGAGGTTGTCTTCCTTG-39), which were pre-
pared according to the tat sequence (Dorn et al., 1990;
oiman et al., 1990). The amplified product was cloned
into the pCR vector. After confirming the sequence, it was
subcloned into the mammalian expression vector
pZeoSV (InVitrogen) at the EcoRI site. This plasmid was
named pZeoSV-tat. The promoter sequences of V70 andV26 were amplified from the l-dash phage vectors con-
aining 59LTR sequences, as described above. The
rimer pair used was 59-GGCCCTCGAGTGTGGGGTTTT-
TATGAGGGGTT-39 and 59-GGCCAAGCTTCGCCAACTG-
TAGGATCTCGA-39, containing XhoI and HindIII restric-
tion sites (underlined), respectively. These promoter se-
quences were cloned into the upstream of the luciferase
gene in the pGL3-Basic vector (Promega, Madison, WI), and
the plasmids were named pGL3-V70 and pGL3-V26, re-
spectively. The sequences in these clones were confirmed.
Promoter activity assay
The promoter activities were determined by the Dual-
Luciferase Reporter (DLR) Assay System using the
pRL-TK vector (Promega) as an internal control. The
pGL3-Basic vector without any promoter and enhancer
sequences and the pGL3-Control vector containing SV40
promoter and enhancer sequences (Promega) were
used as negative and positive controls, respectively.
Cf2Th cells in 12-well microplate were cotransfected with
various plasmid combinations using LipofectAMINE
PLUS reagent (GIBCO BRL, Rockville, MD). Transfection
with these plasmids (1 mg of DNA/well) was performed
using 3 ml of PLUS and 2 ml of LipofectAMINE reagents
per well. Forty-eight hours after transfection, the firefly
luciferase activities produced by pGL vectors and Renilla
luciferase activities produced by pRL-TK vector in each
cell lysate were quantified with a luminometer (Aloka,
Tokyo, Japan). The promoter activities were estimated by
the firefly luciferase activities after normalization by the
Renilla luciferase activities.
Serological tests
Antibody responses against EIAV viral core protein
(Gag p26) were examined by CF, ELISA, and AGID tests
according to previously reported methods with minor
modifications (Kono and Kobayashi, 1966; Nakajima and
Usimi, 1971; Suzuki et al., 1982). The CF test was carried
out according to Kolmer’s method by applying the mi-
cro-CF technique. A mixture of 0.025 ml of serially diluted
serum, 0.025 ml of antigen (4 units), and 0.05 ml of
guinea pig complement (2 units) in each well of a 96-well
microplate was allowed to stand at 4°C for 18 h and then
reacted with 0.05 ml of 1.5% sensitized sheep erythrocyte
suspension for 30 min at 37°C. The antibody titers were
expressed by the reciprocal of the highest dilution of
serum that showed 50% or more inhibition of hemolysis.
For ELISA, the microplates coated with EIAV Gag protein
were reacted with horse serum at a dilution of 1:800 for
20 min at 37°C, followed by horseradish peroxidase-
conjugated anti-horse IgG for 20 min at 37°C. The assay
was repeated twice, and the mean absorbance value of
each serum sample was calculated. The AGID test was
performed using 0.8% agarose gel dissolved in 0.05 M
C138 ZHENG ET AL.Tris–HCl buffer (pH 7.2) containing 0.85% NaCl. The an-
tigen and positive control sera for the AGID test were
prepared as reported previously (Nakajima and Usimi,
1971). The gel diffusion plate was allowed to stand at
room temperature for 48 h, and the reactions were de-
termined by the appearance of precipitation lines.
ACKNOWLEDGMENTS
This work was supported in part by Special Coordination Funds of
the Science and Technology Agency of the Japanese government; a
Grant-in-Aid for Scientific Research on Priority Areas from the Ministry
of Education, Science, Sports and Culture; a Grant-in-Aid for AIDS
Research from the Ministry of Health and Welfare; and a special
Grant-in-Aid for promotion of Education and Science in Hokkaido Uni-
versity provided by the Ministry of Education, Science, Sports and
Culture of Japan.
REFERENCES
Carpenter, S., and Chesebro, B. (1989). Change in host cell tropism
associated with in vitro replication of equine infectious anemia virus.
J. Virol. 63, 2492–2496.
arpenter, S., Alexandersen, S., Long, M. J., Perryman, S., and Chesebro, B.
(1991). Identification of a hypervariable region in the long terminal repeat
of equine infectious anemia virus. J. Virol. 65, 1605–1610.
Carvalho, M., Kirkland, M., and Derse, D. (1993). Protein interactions
with DNA elements in variant equine infectious anemia virus enhanc-
ers and their impact on transcriptional activity. J. Virol. 67, 6586–6595.
Chiu, I.-M., Yaniv, A., Dahlberg, J. E., Gazit, A., Skuntz, S. F., Tronick, S. R.,
and Aaronson, S. A. (1985). Nucleotide sequence evidence for rela-
tionship of AIDS retrovirus to lentiviruses. Nature 317, 366–368.
Cook, R. F., Leroux, C., Cook, S. J., Berger, S. L., Lichtenstein, D. L.,
Ghabrial, N. N., Montelaro, R. C., and Issel, C. J. (1998). Development
and characterization of an in vivo pathogenic molecular clone of
equine infectious anemia virus. J. Virol. 72, 1383–1393.
Dorn, P., DaSilva, L., Martarano, L., and Derse, D. (1990). Equine infec-
tious anemia virus tat: insights into the structure, function, and
evolution of lentivirus trans-activator proteins. J. Virol. 64, 1616–1624.
Fujinaga, K., Zhong, Q., Nakaya, T., Kameoka, M., Meguro, T., Yamada,
K., and Ikuta, K. (1995). Extracellular Nef protein regulates productive
HIV-1 infection from latency. J. Immunol. 155, 5289–5298.
Issel, C. J., and Coggins, L. (1979). Equine infectious anemia: current
knowledge. J. Am. Vet. Med. Assoc. 174, 727–733.
Issel, C. J., Horohov, D. W., Lea, D. F., Adams, W. V., Jr., Hagius, S. D.,
McManus, J. M., Allison, A. C., and Montelaro, R. C. (1992). Efficacy
of inactivated whole-virus and subunit vaccines in preventing infec-
tion and disease caused by equine infectious anemia virus. J. Virol.
66, 3398–3408.
Kawakami, T., Sherman, L., Dahlberg, J., Gazit, A., Yaniv, A., Tronick,
S. R., and Aaronson, S. A. (1987). Nucleotide sequence analysis of
equine infectious anemia virus proviral DNA. Virology 158, 300–312.
Kobayashi, K., and Kono, Y. (1967a). Serial passages of equine infec-
tious anemia virus in horse leukocyte cultures. Natl. Inst. Anim.
Health Q. 7, 1–7.
Kobayashi, K., and Kono, Y. (1967b). Propagation and titration of equine
infectious anemia virus in horse leukocyte cultures. Natl. Inst. Anim.
Health Q. 7, 8–20.
Kono, Y., and Kobayashi, K. (1966). Complement fixation test of equine
infectious anemia. I. Specificity of the test. Natl. Inst. Anim. Health Q.
6, 194–203.
Kono, Y., and Kobayashi, K. (1970). Changes in pathogenicity of equine
infectious anemia virus during passages in horse leukocyte cultures.
Natl. Inst. Anim. Health Q. 10, 106–112.Kono, Y., Kobayashi, K., and Fukunaga, Y. (1970). Immunization of horses
against equine infectious anemia (EIA) with an attenuated EIA virus.
Natl. Inst. Anim. Health Q. 10, 113–122.
Kono, Y., and Yoshino, T. (1974). Propagation of equine infectious ane-
mia virus in horse kidney cell cultures. Natl. Inst. Anim. Health Q. 14,
155–162.
Lichtenstein, D. L., Issel, C. J., and Montelaro, R. C. (1996). Genomic
quasispecies associated with the initiation of infection and disease
in ponies experimentally infected with equine infectious anemia
virus. J. Virol. 70, 3346–3354.
Madden, C. R., and Shih, D. S. (1996). Analysis of the long terminal
repeat from cytopathic strain of equine infectious anemia virus.
Virology 225, 395–399.
Malmquist, W., Barnett, D., and Becvar, D. (1973). Production of equine
infectious anemia antigen in a persistently infected cell line. Arch.
Virol. 42, 361–370.
Maury, W. (1994). Monocyte maturation controls expression of equine
infectious anemia virus. J. Virol. 68, 6270–6279.
Maury, W. J., Carpenter, S., Graves, K., and Chesebro, B. (1994). Cellular
and viral specificity of equine infectious anemia virus tat transacti-
vation. Virology 200, 632–642.
Maury, W., Perryman, S., Oaks, L., Seid, B. K., Crawford, T., McGuire, T.,
and Carpenter, S. (1997). Localized sequence heterogeneity in the
long terminal repeats of in vivo isolates of equine infectious anemia
virus. J. Virol. 71, 4929–4937.
Montelaro, R. C., Ball, J. M., Rwambo, P. M., and Issel, C. J. (1989).
Antigenic variation during persistent lentivirus infections and its
implications for vaccine development: Immunobiology of proteins
and peptides V. Adv. Exp. Med. Biol. 215, 251–272.
Nakajima H., and Usimi, C. (1971). Immunodiffusion studies of purified
equine infectious anemia virus. Inf. Immun. 3, 373–377.
Noiman, S., Gazit, A., Tori, O., Sherman, L., Miki, T., Tronick, S. R., and
Yaniv, A. (1990). Identification of sequences encoding the equine
infectious anemia virus tat gene. Virology 176, 280–288.
Ogawa, K., Shibata, R., Kiyomasu, T., Higuchi, I., Kishida, Y., Ishimoto, A.,
and Adachi, A. (1989). Mutational analysis of the human immunode-
ficiency virus vpr open reading frame. J. Virol. 63, 4110–4114.
Payne, S. L., Rausch, J., Rushlow, K., Montelaro, R. C., Issel, C., Flaherty,
M., Perry, S., Sellon, D., and Fuller, F. (1994). Characterization of
infectious molecular clones of equine infectious anemia virus. J. Gen.
Virol. 75, 425–429.
Payne, S. L., Qi, X.-M., Shao, H., Dwyer, A., and Fuller, F. J. (1998).
Disease induction by virus derived from molecular clones of equine
infectious anemia virus. J. Virol. 72, 483–487.
Payne, S. L., La Celle, K., Pei, X.-F., Qi, X.-M., Shao, H., Steagall, W. K.,
Perry, S., and Fuller, F. (1999). Long terminal repeat sequences of
equine infectious anaemia virus are a major determinant of cell
tropism. J. Gen. Virol. 80, 755–759.
Perry, S. T., Flaherty, M. T., Kelley, M. J., Clabough, D. L., Tronick, S. R.,
Coggins, L., Whetter, L., Lengel, C. R., and Fuller, F. (1992). The
surface envelope protein gene region of equine infectious anemia
virus is not an important determinant of tropism in vitro. J. Virol. 66,
4085–4097.
Rice, N. R., Lequarre, A.-S., Casey, J. W., Lahn, S., Stephens, R. M., and
Edwards, J. (1989). Viral DNA in horses infected with equine infec-
tious anemia virus. J. Virol. 63, 5194–5200.
Sellon, D. C., Perry, S. T., Coggins, L., and Fuller, F. J. (1992). Wild-type
equine infectious anemia virus replicates in vivo predominantly in
tissue macrophages, not in peripheral blood monocytes. J. Virol. 66,
5906–5913.
Sellon, D. C., Fuller, F. J., and McGuire, T. C. (1994). The immunopatho-
genesis of equine infectious anemia virus. Virus Res. 32, 111–138.Sellon, D. C., Walker, K. M., Russell, K. E., Perry, S. T., Covington, P., and
Fuller, F. J. (1996). Equine infectious anemia virus replication is
SS
S
W
Y
Z
Z
139REPLICATION OF EIAV AVIRULENT STRAINupregulated during differentiation of blood monocytes from acutely
infected horses. J. Virol. 70, 590–594.
hen, R.-X. (1983). Development and use of an equine infectious ane-
mia donkey leukocyte attenuated vaccine. In “Proceedings on the
International Symposium on Immunity to Equine Infection Anemia,”
pp. 34–53. Harbin Veterinary Research Institute, Chinese Academy of
Agricultural Sciences, Harbin, People’s Republic of China.
hen, R.-X., Wang, Z.-Y., Liu, G.-R., and Liu, L.-J. (1990). The cross-immunity
of EIA donkey leukocyte-attenuated vaccine to American Wyoming virus
strain. In “Studies On Immunization Against Equine Infection Anemia,”
pp. 49–57. Harbin Veterinary Research Institute, Chinese Academy of
Agricultural Sciences, Harbin, People’s Republic of China.
uzuki, T., Ueda, S., and Samejima, T. (1982). Emzyme-linked immu-
nosorbent assay for diagnosis of equine infectious anemia. Vet.
Microbiol. 7, 307–316.
hetter, L., Archambault, D., Perry, S., Gazit, A., Coggins, L., Yaniv, A.,Clabough, D., Dahlberg, J., Fuller, F., and Tronick, S. (1990). Equine
infectious anemia virus derived from a molecular clone persistently
infects horses. J. Virol. 64, 5750–5756.
u, L. (1996). Equine infectious anemia. In “Lentiviruses and Related
Diseases,” 1st ed. (L. Yu and X. F. Zhang, Eds.), pp. 229–232, Chap. 4.
Chinese Publishing House of Agricultural Science and Technology,
Peking, People’s Republic of China. (Chinese)
heng, Y.-H., Nakaya, T., Sentsui, H., Kameoka, M., Kishi, M., Hagiwara,
K., Takahashi, H., Kono, Y., and Ikuta, K. (1997a). Insertions, duplica-
tions and substitutions in restricted gp90 regions of equine infec-
tious anaemia virus during febrile episodes in an experimentally
infected horse. J. Gen. Virol. 78, 807–820.
heng, Y.-H., Sentsui, H., Nakaya, T., Kono, Y., and Ikuta, K. (1997). In vivo
dynamics of equine infectious anemia viruses emerging during fe-
brile episodes: insertions/duplications at the principal neutralizing
domain. J. Virol. 71, 5031–5039.
